NLRP3 Inflammasome Activation Among Patients During Acute Gout Flares

NCT05744297 — Unknown, 10 participants, Centre Hospitalier Saint Joseph Saint Luc de Lyon

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

Registry	NCT05744297, acronym ActiNG
Status	Unknown
Study type	Observational
Enrollment	10 (Estimated)
Sponsor	Centre Hospitalier Saint Joseph Saint Luc de Lyon (Other)
Conditions	Gout Arthritis
Dates	start 2023-04-28, primary completion 2023-06-01 (estimated), completion 2023-10-01 (estimated), first posted 2023-02-27, last updated 2023-05-12
Locations	1 site in France

-Summary

Gout is a chronic joint disease associated with deposition of monosodium urate crystals, as a consequence of hyperuricemia. Gout is an intermittent flaring condition and acute gout flares are driven by NLRP3 inflammasome and IL1-beta production.

However pathogenesis of acute gout flares remains poorly known in vivo in human.

The aim of this study is to evaluate NLRP3 inflammasome activation in vivo in patients cells during acute gout flares.

Expand all sections · Collapse all

+Detailed description

Blood and synovial fluid will be obtained from remainder of patients' samples during an acute gout flares. White blood cells will be isolated and NLRP3 inflammasome activation will be assessed. Then, NLRP3 inflammasome inhibitors will be tested on cells with NLRP3 inflammasome activity.

+Outcome measures

Primary outcomes

NLRP3 inflammasome activation in white blood cells. [Patient admission at hospital]: White blood cells will be isolated from blood sample and NLRP3 inflammasome activation will be assessed by flow cytometry.

Secondary outcomes

NLRP3 inflammasome activation in synovial cells. [Patient admission at hospital]: Nucleated cells will be isolated from synovial fluid sample and NLRP3 inflammasome activation will be assessed by flow cytometry.
Effects of NLRP3 inflammasome inhibitors on proportion of NLRP3 inflammasome activation in white blood cells/synovial cells [up to 7 days after analysis of NLRP3 activity]: NLRP3 inflammasome inhibitors will be tested on cells with NLRP3 inflammasome activity in blood or synovial fluid.

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Hospitalization for acute gout flare confirmed by joint fluid analysis or Nijmegen score > 8
* Aged > 18

Exclusion Criteria:

* Gout treatment already started
* Inflammatory Arthritis other than Gout Arthritis
* Pregnant or breast feeding women
* Patient protected by law

+Locations (1)

Facility	City	Country	Status
Centre Hospitalier Saint Joseph Saint Luc	Lyon	France	Recruiting